An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) [Estudio abierto, de múltiples brazos de tratamiento, no comparativo para evaluar la seguridad y tolerabilidad de canakinumab (ACZ885) en pacientes con artritis idiopática juvenil sistémica (AIJS) activa.]
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Canakinumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Registrational
- Acronyms Beta-SPECIFIC-4Pa
- Sponsors Novartis
- 02 Feb 2013 Planned number of patients changed from 220 to 239 as reported by European Clinical Trials Database record.
- 02 Feb 2013 New source identified and integrated (European Clinical Trials Database record: EudraCT2012-003054-92).
- 24 Jan 2013 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database record.